Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 1/07/14 → 30/06/17 |
Funding
- Amgen Australia Pty Ltd: A$1,589,928.00
A Double-blind, Randomized, Placebo Controlled Single Site Study to Evaluate the Effects of Evolocumab (AMG 145) Treatment Alone and in Combination with Atorvastatin on Lipoprotein Kinetics
- Barrett, Hugh (Chief Investigator)
- Watts, Gerald (Investigator 02)